RU2765877C1 - Биореактор для транскрипции рнк in vitro - Google Patents

Биореактор для транскрипции рнк in vitro Download PDF

Info

Publication number
RU2765877C1
RU2765877C1 RU2020141236A RU2020141236A RU2765877C1 RU 2765877 C1 RU2765877 C1 RU 2765877C1 RU 2020141236 A RU2020141236 A RU 2020141236A RU 2020141236 A RU2020141236 A RU 2020141236A RU 2765877 C1 RU2765877 C1 RU 2765877C1
Authority
RU
Russia
Prior art keywords
reaction vessel
bioreactor
dna
magnetic
rna
Prior art date
Application number
RU2020141236A
Other languages
English (en)
Russian (ru)
Inventor
Беньямин ЯЗДАН ПАНАХ
Тильманн РООС
Мартин КУНЦЕ
Феликс БЕРЧ
Аниэла ВОХНЕР
Михаэль РАУЭН
Филипп Хоффманн
Original Assignee
Кьюрвак Аг
Тесла Аутомацион Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кьюрвак Аг, Тесла Аутомацион Гмбх filed Critical Кьюрвак Аг
Application granted granted Critical
Publication of RU2765877C1 publication Critical patent/RU2765877C1/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6865—Promoter-based amplification, e.g. nucleic acid sequence amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F33/00—Other mixers; Mixing plants; Combinations of mixers
    • B01F33/45—Magnetic mixers; Mixers with magnetically driven stirrers
    • B01F33/451—Magnetic mixers; Mixers with magnetically driven stirrers wherein the mixture is directly exposed to an electromagnetic field without use of a stirrer, e.g. for material comprising ferromagnetic particles or for molten metal
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F33/00—Other mixers; Mixing plants; Combinations of mixers
    • B01F33/45—Magnetic mixers; Mixers with magnetically driven stirrers
    • B01F33/452—Magnetic mixers; Mixers with magnetically driven stirrers using independent floating stirring elements
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F35/00—Accessories for mixers; Auxiliary operations or auxiliary devices; Parts or details of general application
    • B01F35/50—Mixing receptacles
    • B01F35/53—Mixing receptacles characterised by the configuration of the interior, e.g. baffles for facilitating the mixing of components
    • B01F35/531—Mixing receptacles characterised by the configuration of the interior, e.g. baffles for facilitating the mixing of components with baffles, plates or bars on the wall or the bottom
    • B01F35/5312—Mixing receptacles characterised by the configuration of the interior, e.g. baffles for facilitating the mixing of components with baffles, plates or bars on the wall or the bottom with vertical baffles mounted on the walls
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F35/00—Accessories for mixers; Auxiliary operations or auxiliary devices; Parts or details of general application
    • B01F35/90—Heating or cooling systems
    • B01F35/92—Heating or cooling systems for heating the outside of the receptacle, e.g. heated jackets or burners
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M21/00—Bioreactors or fermenters specially adapted for specific uses
    • C12M21/18—Apparatus specially designed for the use of free, immobilized or carrier-bound enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M27/00—Means for mixing, agitating or circulating fluids in the vessel
    • C12M27/02—Stirrer or mobile mixing elements
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/48—Automatic or computerized control
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/1013—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by using magnetic beads
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F35/00—Accessories for mixers; Auxiliary operations or auxiliary devices; Parts or details of general application
    • B01F35/90—Heating or cooling systems
    • B01F2035/98—Cooling
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F35/00—Accessories for mixers; Auxiliary operations or auxiliary devices; Parts or details of general application
    • B01F35/90—Heating or cooling systems
    • B01F2035/99—Heating
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F2101/00—Mixing characterised by the nature of the mixed materials or by the application field
    • B01F2101/22—Mixing of ingredients for pharmaceutical or medical compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/10—Nucleotidyl transfering
    • C12Q2521/119—RNA polymerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/143—Magnetism, e.g. magnetic label

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Sustainable Development (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Computer Hardware Design (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
RU2020141236A 2018-06-28 2019-06-28 Биореактор для транскрипции рнк in vitro RU2765877C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2018/067504 2018-06-28
EP2018067504 2018-06-28
PCT/EP2019/067323 WO2020002598A1 (en) 2018-06-28 2019-06-28 Bioreactor for rna in vitro transcription

Publications (1)

Publication Number Publication Date
RU2765877C1 true RU2765877C1 (ru) 2022-02-04

Family

ID=62837899

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020141236A RU2765877C1 (ru) 2018-06-28 2019-06-28 Биореактор для транскрипции рнк in vitro

Country Status (13)

Country Link
US (2) US12371646B2 (https=)
EP (2) EP4273266A3 (https=)
JP (1) JP7352581B2 (https=)
KR (1) KR20210027368A (https=)
CN (2) CN112334579B (https=)
AU (1) AU2019293714C1 (https=)
BR (1) BR112020025601A8 (https=)
CA (1) CA3102135A1 (https=)
IL (1) IL279759B2 (https=)
MX (1) MX2020013148A (https=)
RU (1) RU2765877C1 (https=)
SG (1) SG11202011097YA (https=)
WO (1) WO2020002598A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU236741U1 (ru) * 2024-12-19 2025-08-19 Федеральное государственное автономное образовательное учреждение высшего образования "Дальневосточный федеральный университет" (ДВФУ) Модуль температурной системы биореактора

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
RU2658490C2 (ru) 2012-03-27 2018-06-21 Кьюрвак Аг Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов
AU2014310935B2 (en) 2013-08-21 2019-11-21 CureVac SE Combination vaccine
BR112016001192A2 (pt) 2013-08-21 2017-08-29 Curevac Ag Vacina contra a raiva
BR112016003361A2 (pt) 2013-08-21 2017-11-21 Curevac Ag vacina do vírus sincicial respiratório (rsv)
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
WO2015135558A1 (en) 2014-03-12 2015-09-17 Curevac Gmbh Combination of vaccination and ox40 agonists
DE202015010000U1 (de) 2014-12-12 2023-07-03 CureVac SE Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
DK3294885T3 (da) 2015-05-08 2020-08-10 Curevac Real Estate Gmbh Fremgangsmåde til at fremstille rna
PL4108769T3 (pl) 2015-05-29 2024-02-05 CureVac Manufacturing GmbH Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznym
US11413346B2 (en) 2015-11-09 2022-08-16 Curevac Ag Rotavirus vaccines
EP3701963A1 (en) 2015-12-22 2020-09-02 CureVac AG Method for producing rna molecule compositions
US11723967B2 (en) 2016-02-17 2023-08-15 CureVac SE Zika virus vaccine
EP3423595A1 (en) 2016-03-03 2019-01-09 CureVac AG Rna analysis by total hydrolysis
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
EP4631970A3 (en) 2016-05-04 2026-01-07 CureVac SE Nucleic acid molecules and uses thereof
WO2018115525A1 (en) 2016-12-23 2018-06-28 Curevac Ag Lassa virus vaccine
EP3558356A2 (en) 2016-12-23 2019-10-30 CureVac AG Mers coronavirus vaccine
AU2018240515B2 (en) 2017-03-24 2024-07-25 CureVac SE Nucleic acids encoding CRISPR-associated proteins and uses thereof
WO2018211038A1 (en) 2017-05-17 2018-11-22 Curevac Ag Method for determining at least one quality parameter of an rna sample
US11602557B2 (en) 2017-08-22 2023-03-14 Cure Vac SE Bunyavirales vaccine
EP3707271A1 (en) 2017-11-08 2020-09-16 CureVac AG Rna sequence adaptation
EP3723796A1 (en) 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
EP3728634A1 (en) 2017-12-21 2020-10-28 CureVac AG Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
CA3091558A1 (en) 2018-04-17 2019-10-24 Curevac Ag Novel rsv rna molecules and compositions for vaccination
BR112020025601A8 (pt) 2018-06-28 2022-07-05 Tesla Automation GmbH Biorreator para a transcrição in vitro de rna
US11421226B2 (en) * 2018-10-17 2022-08-23 Ramot At Tel-Aviv University Ltd. Programmable artificial cell
TW202039534A (zh) 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
US12492425B2 (en) 2018-12-21 2025-12-09 CureVac SE Methods for RNA analysis
KR20220121246A (ko) 2019-12-20 2022-08-31 큐어백 아게 핵산 전달용 신규한 지질 나노입자
MX2022009460A (es) 2020-02-04 2022-12-16 Curevac Ag Vacuna contra el coronavirus.
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
EP4132478A1 (en) 2020-04-09 2023-02-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
WO2021222856A1 (en) * 2020-05-01 2021-11-04 Helix Nanotechnologies, Inc. Compositions and methods for rna synthesis
JP7789698B2 (ja) * 2020-05-12 2025-12-22 ハラランボス・マカソリス Ｒｎａを用いた治療薬の合成方法及び合成モジュール式装置
GB2597436B (en) * 2020-05-12 2025-03-26 Makatsoris Charalampos A method and apparatus for RNA synthesis
MX2022015132A (es) 2020-05-29 2023-03-08 CureVac SE Vacunas combinadas a base de acidos nucleicos.
CA3170743A1 (en) 2020-08-31 2022-03-03 Susanne RAUCH Multivalent nucleic acid based coronavirus vaccines
US20240246056A1 (en) 2020-09-01 2024-07-25 CureVac RNA Printer GmbH Manufacturing device for a pharmaceutical product
JP2023546175A (ja) 2020-10-14 2023-11-01 ジョージ・メイソン・リサーチ・ファウンデーション・インコーポレイテッド 脂質ナノ粒子製造の方法及びそれに由来する組成物
EP4232569B1 (en) * 2020-10-23 2026-03-11 LineaRX, Inc. Compositions and methods for rna synthesis
JP7641487B2 (ja) 2020-11-27 2025-03-07 キュアバック マニュファクチャリング ゲーエムベーハー キャピラリーポリメラーゼ連鎖反応によってｄｎａ産物を調製するためのデバイス
WO2022137133A1 (en) 2020-12-22 2022-06-30 Curevac Ag Rna vaccine against sars-cov-2 variants
US20240156946A1 (en) 2020-12-22 2024-05-16 CureVac SE Rna vaccine against sars-cov-2 variants
WO2022178357A1 (en) * 2021-02-22 2022-08-25 The Board Of Regents Of The University Of Texas System Magnetic description magnetic shear bioreactor apparatus and methods
US20240181037A1 (en) 2021-03-26 2024-06-06 Glaxosmithkline Biologicals Sa Immunogenic compositions
WO2022261050A1 (en) * 2021-06-07 2022-12-15 The University Of Massachusetts Apparatus and method for continuous production of rna
EP4508440A1 (en) 2022-04-15 2025-02-19 Quantoom Biosciences S.A. System and method for the production of rna
BE1030468B1 (fr) 2022-04-20 2023-11-21 Quantoom Biosciences S A Système et méthode pour la production d’arn
CN114540444B (zh) * 2022-04-23 2022-08-09 江苏申基生物科技有限公司 一种加帽组合物及其制备方法和体外转录反应体系
CN115106356B (zh) * 2022-07-06 2023-06-06 眉山市城投中恒能环保科技有限公司 一种用于餐厨垃圾回收的处理方法及处理系统
CN119947747A (zh) 2022-09-26 2025-05-06 葛兰素史克生物有限公司 流感病毒疫苗
EP4344769B1 (en) * 2022-09-30 2025-03-19 Technische Universität Clausthal System for continuous manufacture of biomolecules
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
CN116180478A (zh) * 2023-02-28 2023-05-30 江苏理文造纸有限公司 一种利用秸秆自动化造纸装置
KR20250169557A (ko) 2023-03-17 2025-12-03 퀀툼 바이오사이언스 에스.에이. 핵산 분자 생산용 장치 및 방법
WO2024209418A1 (en) * 2023-04-07 2024-10-10 BioNTech SE Heating and cooling jacket for fluid vessels
EP4713483A1 (en) 2023-05-16 2026-03-25 CureVac RNA Printer GmbH Improved rna in vitro transcription using dna beads
WO2025022178A2 (en) * 2023-07-24 2025-01-30 Apte Zachary Schulz In-situ mrna vaccine production method and device
WO2025040263A1 (en) 2023-08-24 2025-02-27 CureVac Manufacturing GmbH Purification process for in vitro amplified dna
KR20250047212A (ko) * 2023-09-27 2025-04-03 포항공과대학교 산학협력단 미세 유체 반응 장치 및 이를 이용한 mRNA 합성 방법
CN119709730A (zh) * 2023-09-28 2025-03-28 康码（上海）生物科技有限公司 一种dna微球及其制备方法和应用
WO2025132839A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Biologicals Sa Influenza virus vaccines
WO2025144938A1 (en) 2023-12-26 2025-07-03 Emmune, Inc. Systems for nucleic acid transfer
GB202406294D0 (en) 2024-05-06 2024-06-19 Thermo Fisher Scientific Baltics Uab Methods and compositions for producing capped mRNA
EP4660288A1 (en) * 2024-06-07 2025-12-10 Sartorius Stedim Biotech GmbH Bioreactor, bioreactor vessel and closure component for a bioreactor vessel
EP4660291A1 (en) 2024-06-07 2025-12-10 Sartorius Stedim Biotech GmbH Bioreactor and bioreactor vessel
WO2026003316A1 (en) * 2024-06-28 2026-01-02 BioNTech SE Method for pcr
CN120115054B (zh) * 2025-05-08 2025-08-05 南京航空航天大学 一种月面基地夹层壳体粉末混粉方法及夹层壳体结构

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038278A1 (en) * 2002-08-12 2004-02-26 George Tzertzinis Methods and compositions relating to gene silencing
US20150090664A1 (en) * 2012-05-15 2015-04-02 Life Technologies As Sample Holder with Magnetic Base and Magnetisable Body
US20160024139A1 (en) * 2013-03-15 2016-01-28 Glaxosmithkline Biologicals Sa Rna purification methods
WO2016062788A1 (en) * 2014-10-24 2016-04-28 Ait Austrian Institute Of Technology Gmbh Microfluidic chip for biological analysis
RU2630999C2 (ru) * 2012-03-09 2017-09-15 Байонир Корпорейшн Композиции для реакции обратной транскрипции с горячим стартом или для полимеразной цепной реакции с обратной транскрипцией с горячим стартом

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2898565A (en) * 1954-07-02 1959-08-04 Mc Graw Edison Co Magnetic core
SE460706B (sv) * 1987-12-30 1989-11-13 Stefan Loefgren Omroerningsorgan
US6884357B2 (en) * 1995-02-21 2005-04-26 Iqbal Waheed Siddiqi Apparatus and method for processing magnetic particles
US6955793B1 (en) * 1997-06-18 2005-10-18 Arencibia Jr Jose P Temperature controlled reaction vessel
US6361749B1 (en) * 1998-08-18 2002-03-26 Immunivest Corporation Apparatus and methods for magnetic separation
CA2366543A1 (en) * 1999-04-09 2000-10-19 John Vellinger Multistage electromagnetic separator for purifying cells, chemicals and protein structures
ATE490267T1 (de) 2001-06-05 2010-12-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt, kodierend für ein virales antigen
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
FI20051248A7 (fi) 2005-12-02 2007-06-03 Biocontrol Systems Oy Biologisten komponenttien rikastusyksikkö ja rikastusmenetelmä
DE102006035618A1 (de) 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
GB0724404D0 (en) 2007-05-29 2008-01-30 Invitrogen Dynal As A sample vessel retaining portion
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
EP2176408B9 (en) 2008-01-31 2015-11-11 Curevac GmbH NUCLEIC ACIDS COMPRISING FORMULA (NuGiXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
WO2010006328A2 (en) * 2008-07-11 2010-01-14 The General Hospital Corporation Magnetic apparatus for blood separation
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
BRPI0914098A2 (pt) * 2008-10-16 2015-11-17 Koninkl Philips Electronics Nv biosensor
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
GB2481425A (en) 2010-06-23 2011-12-28 Iti Scotland Ltd Method and device for assembling polynucleic acid sequences
CA2801523C (en) 2010-07-30 2021-08-03 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
EP2623121A1 (en) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
RU2658490C2 (ru) 2012-03-27 2018-06-21 Кьюрвак Аг Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов
SG10201607962RA (en) 2012-03-27 2016-11-29 Curevac Ag Artificial nucleic acid molecules
WO2013143700A2 (en) 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules comprising a 5'top utr
WO2013174409A1 (en) 2012-05-25 2013-11-28 Curevac Gmbh Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
RU2718988C2 (ru) 2013-02-22 2020-04-15 Куревак Аг Комбинация противораковой рнк-вакцины и ингибитора пути pd-1 и ее применение
WO2014152031A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Ribonucleic acid purification
BR112016001192A2 (pt) 2013-08-21 2017-08-29 Curevac Ag Vacina contra a raiva
WO2015024664A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Composition and vaccine for treating prostate cancer
AU2014310935B2 (en) 2013-08-21 2019-11-21 CureVac SE Combination vaccine
BR112016003361A2 (pt) 2013-08-21 2017-11-21 Curevac Ag vacina do vírus sincicial respiratório (rsv)
DK3035955T3 (da) 2013-08-21 2019-12-02 Curevac Ag Sammensætning og vaccine til behandling af lungekræft
SG11201510747RA (en) 2013-08-21 2016-03-30 Curevac Ag Method for increasing expression of rna-encoded proteins
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
KR102399799B1 (ko) 2013-12-30 2022-05-18 큐어백 아게 인공 핵산 분자
SG11201604198YA (en) 2013-12-30 2016-07-28 Curevac Ag Methods for rna analysis
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
WO2015135558A1 (en) 2014-03-12 2015-09-17 Curevac Gmbh Combination of vaccination and ox40 agonists
CA2936286A1 (en) 2014-04-01 2015-10-08 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
US10837039B2 (en) * 2014-06-10 2020-11-17 Curevac Real Estate Gmbh Methods and means for enhancing RNA production
WO2016023961A1 (en) * 2014-08-12 2016-02-18 Abb Technology Ag Magnet having regions of different magnetic properties and method for forming such a magnet
DE202015010000U1 (de) 2014-12-12 2023-07-03 CureVac SE Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
CA2962849A1 (en) 2014-12-16 2016-06-23 Curevac Ag Ebolavirus and marburgvirus vaccines
KR102580696B1 (ko) 2014-12-30 2023-09-19 큐어백 에스이 신규 인공 핵산 분자
EP3283059B1 (en) 2015-04-13 2024-01-03 CureVac Manufacturing GmbH Method for producing rna compositions
SG11201707663SA (en) 2015-04-17 2017-11-29 Curevac Ag Lyophilization of rna
RU2749113C2 (ru) 2015-04-22 2021-06-04 Куревак Аг Содержащая рнк композиция для лечения опухолевых заболеваний
US20180208957A1 (en) 2015-04-30 2018-07-26 Curevac Ag Method for in vitro transcription using an immobilized restriction enzyme
ES2897823T3 (es) 2015-04-30 2022-03-02 Curevac Ag Poli(N)polimerasa inmovilizada
DK3294885T3 (da) 2015-05-08 2020-08-10 Curevac Real Estate Gmbh Fremgangsmåde til at fremstille rna
KR20180004820A (ko) 2015-05-15 2018-01-12 큐어백 아게 적어도 하나의 mRNA 구성의 투여를 포함하는 신규 프라임-부스트 요법
EP3297682B1 (en) 2015-05-20 2021-07-14 CureVac AG Dry powder composition comprising long-chain rna
WO2016184575A1 (en) 2015-05-20 2016-11-24 Curevac Ag Dry powder composition comprising long-chain rna
PL4108769T3 (pl) 2015-05-29 2024-02-05 CureVac Manufacturing GmbH Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznym
EP4098743A1 (en) 2015-05-29 2022-12-07 CureVac AG Method for adding cap structures to rna using immobilized enzymes
US20180296663A1 (en) 2015-06-17 2018-10-18 Curevac Ag Vaccine composition
US20190017100A1 (en) 2015-07-01 2019-01-17 Curevac Ag Method for analysis of an rna molecule
WO2017009376A1 (en) 2015-07-13 2017-01-19 Curevac Ag Method of producing rna from circular dna and corresponding template dna
WO2017021546A1 (en) 2015-08-05 2017-02-09 Curevac Ag Epidermal mrna vaccine
DK3332019T3 (da) 2015-08-07 2020-02-17 Curevac Ag Fremgangsmåde til in vivo-produktionen af rna i en værtscelle
WO2017025447A1 (en) 2015-08-10 2017-02-16 Curevac Ag Method of increasing the replication of a circular dna molecule
CA2992801A1 (en) 2015-08-28 2017-03-09 Curevac Ag Artificial nucleic acid molecules
ES2964690T3 (es) 2015-09-21 2024-04-09 Trilink Biotechnologies Llc Método para sintetizar ARN con caperuza 5'
US11225682B2 (en) 2015-10-12 2022-01-18 Curevac Ag Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
US11413346B2 (en) 2015-11-09 2022-08-16 Curevac Ag Rotavirus vaccines
JP2017085951A (ja) 2015-11-09 2017-05-25 株式会社リコー 治具、処理装置、処理方法及びｃＤＮＡ合成方法
EP3374504B1 (en) 2015-11-09 2025-03-19 CureVac SE Optimized nucleic acid molecules
WO2017090134A1 (ja) 2015-11-25 2017-06-01 神栄テクノロジー株式会社 粒子センサ
US20180371392A1 (en) 2015-12-21 2018-12-27 Curevac Ag Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay
EP3701963A1 (en) 2015-12-22 2020-09-02 CureVac AG Method for producing rna molecule compositions
EP3394280A1 (en) 2015-12-23 2018-10-31 CureVac AG Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
WO2017140345A1 (en) 2016-02-15 2017-08-24 Curevac Ag Method for analyzing by-products of rna in vitro transcription
US11723967B2 (en) 2016-02-17 2023-08-15 CureVac SE Zika virus vaccine
EP3423595A1 (en) 2016-03-03 2019-01-09 CureVac AG Rna analysis by total hydrolysis
US20190177714A1 (en) 2016-03-24 2019-06-13 Curevac Ag Immobilized inorganic pyrophosphatase (ppase)
EP3777881A1 (en) 2016-04-22 2021-02-17 CureVac AG Rna encoding a tumor antigen
WO2017186928A1 (en) 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
EP4631970A3 (en) 2016-05-04 2026-01-07 CureVac SE Nucleic acid molecules and uses thereof
EP4233898A3 (en) 2016-05-04 2023-11-01 CureVac SE Influenza mrna vaccines
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
US20180126003A1 (en) 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
WO2017203008A1 (en) 2016-05-25 2017-11-30 Curevac Ag Novel biomarkers
WO2017212008A1 (en) 2016-06-09 2017-12-14 Curevac Ag Hybrid carriers for nucleic acid cargo
WO2017212007A1 (en) 2016-06-09 2017-12-14 Curevac Ag Cationic carriers for nucleic acid delivery
WO2017212009A1 (en) 2016-06-09 2017-12-14 Curevac Ag Hybrid carriers for nucleic acid cargo
WO2017212006A1 (en) 2016-06-09 2017-12-14 Curevac Ag Hybrid carriers for nucleic acid cargo
MX2019001920A (es) 2016-08-19 2019-07-01 Curevac Ag Arn la terapia contra el cancer.
WO2018041921A1 (en) 2016-08-31 2018-03-08 Curevac Ag Mixing device for the production of a liquid nucleic acid composition
JP2018057333A (ja) 2016-10-06 2018-04-12 株式会社リコー 処理キット、処理方法、ｃＤＮＡの合成方法及び処理装置
US10487105B2 (en) 2016-10-19 2019-11-26 Arcturus Therapeutics, Inc. Trinucleotide MRNA cap analogs
BR112019008481A2 (pt) 2016-10-26 2020-03-03 Curevac Ag Vacinas de mrna de nanopartículas lipídicas
US11279923B2 (en) 2016-11-28 2022-03-22 Curevac Ag Method for purifying RNA
EP3551230A1 (en) 2016-12-08 2019-10-16 CureVac AG Rna for treatment or prophylaxis of a liver disease
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
WO2018115525A1 (en) 2016-12-23 2018-06-28 Curevac Ag Lassa virus vaccine
EP3558356A2 (en) 2016-12-23 2019-10-30 CureVac AG Mers coronavirus vaccine
EP3558355A2 (en) 2016-12-23 2019-10-30 CureVac AG Henipavirus vaccine
CA3050614A1 (en) 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
CN106916743B (zh) 2017-03-19 2019-02-12 北京化工大学 一体化核酸提取与扩增检测系统
AU2018240515B2 (en) 2017-03-24 2024-07-25 CureVac SE Nucleic acids encoding CRISPR-associated proteins and uses thereof
WO2018211038A1 (en) 2017-05-17 2018-11-22 Curevac Ag Method for determining at least one quality parameter of an rna sample
RU2020103379A (ru) 2017-07-04 2021-08-04 Куревак Аг Новые молекулы нуклеиновых кислот
US11602557B2 (en) 2017-08-22 2023-03-14 Cure Vac SE Bunyavirales vaccine
CN111630173A (zh) 2017-10-19 2020-09-04 库瑞瓦格股份公司 新型人工核酸分子
EP3707271A1 (en) 2017-11-08 2020-09-16 CureVac AG Rna sequence adaptation
EP3723796A1 (en) 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
EP3728634A1 (en) 2017-12-21 2020-10-28 CureVac AG Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
WO2019193183A2 (en) 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
CA3091558A1 (en) 2018-04-17 2019-10-24 Curevac Ag Novel rsv rna molecules and compositions for vaccination
WO2020002525A1 (en) 2018-06-27 2020-01-02 Curevac Ag Novel lassa virus rna molecules and compositions for vaccination
BR112020025601A8 (pt) 2018-06-28 2022-07-05 Tesla Automation GmbH Biorreator para a transcrição in vitro de rna
TW202039534A (zh) 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
CA3118034A1 (en) 2018-12-21 2020-06-25 Curevac Ag Rna for malaria vaccines
US12492425B2 (en) 2018-12-21 2025-12-09 CureVac SE Methods for RNA analysis
US20220133908A1 (en) 2019-02-08 2022-05-05 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
US20220313813A1 (en) 2019-06-18 2022-10-06 Curevac Ag Rotavirus mrna vaccine
EP4013880A1 (en) 2019-08-14 2022-06-22 CureVac AG Rna combinations and compositions with decreased immunostimulatory properties
KR20220121246A (ko) 2019-12-20 2022-08-31 큐어백 아게 핵산 전달용 신규한 지질 나노입자
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
MX2022015132A (es) 2020-05-29 2023-03-08 CureVac SE Vacunas combinadas a base de acidos nucleicos.
WO2021254593A1 (en) 2020-06-15 2021-12-23 Curevac Ag Analysis of nucleic acid mixtures

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038278A1 (en) * 2002-08-12 2004-02-26 George Tzertzinis Methods and compositions relating to gene silencing
RU2630999C2 (ru) * 2012-03-09 2017-09-15 Байонир Корпорейшн Композиции для реакции обратной транскрипции с горячим стартом или для полимеразной цепной реакции с обратной транскрипцией с горячим стартом
US20150090664A1 (en) * 2012-05-15 2015-04-02 Life Technologies As Sample Holder with Magnetic Base and Magnetisable Body
US20160024139A1 (en) * 2013-03-15 2016-01-28 Glaxosmithkline Biologicals Sa Rna purification methods
WO2016062788A1 (en) * 2014-10-24 2016-04-28 Ait Austrian Institute Of Technology Gmbh Microfluidic chip for biological analysis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MURZABAEV ET AL, Handmade microfluidic device for biochemical applications in emulsion // Journal of Bioscience and Bioengineering, Volume 121, Issue 4, April 2016, pp. 471-476. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU236741U1 (ru) * 2024-12-19 2025-08-19 Федеральное государственное автономное образовательное учреждение высшего образования "Дальневосточный федеральный университет" (ДВФУ) Модуль температурной системы биореактора

Also Published As

Publication number Publication date
CN112334579A (zh) 2021-02-05
JP7352581B2 (ja) 2023-09-28
CA3102135A1 (en) 2020-01-02
EP3814495A1 (en) 2021-05-05
BR112020025601A8 (pt) 2022-07-05
JP2021528051A (ja) 2021-10-21
EP4273266A3 (en) 2024-03-13
EP3814495B1 (en) 2023-06-07
US12371646B2 (en) 2025-07-29
IL279759A (en) 2021-03-01
IL279759B2 (en) 2026-02-01
KR20210027368A (ko) 2021-03-10
MX2020013148A (es) 2021-03-02
US20210261897A1 (en) 2021-08-26
EP3814495C0 (en) 2023-06-07
US20250313788A1 (en) 2025-10-09
AU2019293714A1 (en) 2020-11-12
CN121628760A (zh) 2026-03-10
BR112020025601A2 (pt) 2021-03-23
IL279759B1 (en) 2025-10-01
WO2020002598A1 (en) 2020-01-02
AU2019293714B2 (en) 2023-03-30
AU2019293714C1 (en) 2023-09-21
EP4273266A2 (en) 2023-11-08
CN112334579B (zh) 2026-01-16
SG11202011097YA (en) 2020-12-30

Similar Documents

Publication Publication Date Title
RU2765877C1 (ru) Биореактор для транскрипции рнк in vitro
JP2021528051A5 (https=)
JPWO2020002598A5 (https=)
JP5657886B2 (ja) 反応器
US20240246056A1 (en) Manufacturing device for a pharmaceutical product
EP4251323B1 (en) A device for preparing a dna product by means of capillary polymerase chain reaction
JP2018537676A (ja) 一体型サンプル処理システム
US20250115896A1 (en) System and method for the production of rna
WO2022098747A1 (en) Nucleic acid synthesis device and methods of use
EP3802781A1 (en) Lysis coil apparatus and uses thereof for isolation and purification of polynucleotides
KR20250169557A (ko) 핵산 분자 생산용 장치 및 방법
CN121605199A (zh) 使用dna珠粒的改进的rna的体外转录
CN117305081A (zh) 用于体积测量的包括压力传感器的生物分子生产系统